Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/mesothelin-dependent cell attachment

被引：59

作者：

Bergan, Lindsay ^{[1
]}

Gross, Jennifer A. ^{[1
]}

Nevin, Barry ^{[1
]}

Urban, Nicole ^{[1
]}

Scholler, Nathalie ^{[1
]}

机构：

[1] Fred Hutchinson Canc Res Ctr, Mol Diagnost Progarm, Seattle, WA 98109 USA

来源：

CANCER LETTERS | 2007年 / 255卷 / 02期

关键词：

mesothelin; CA125; biobody; tumor cell attachment; ovarian cancer; peritoneal metastasis;

D O I：

10.1016/j.canlet.2007.04.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Preventing peritoneal implantation of carcinoma cells could prolong ovarian cancer patient remission and survival. Peritoneal cells constitutively express mesothelin, a ligand for CA 125 that is expressed by tumor cells. Thus blocking CA 125/ mesothelin-dependent cell attachment may prevent or delay peritoneal metastatic recurrence. We developed a high-throughput screening system for reagents able to block CA125/mesothelin-dependent cell attachment with a sensitive quantitative readout. Using a novel yeast-expression system to produce secreted, in vivo biotinylated proteins and biobodies (Bbs), we generated anti-mesothelin Bbs. Anti-mesothelin Bbs derived from high affinity yeast-display scFv detected both membrane-bound and soluble mesothelins and inhibited CA125/mesothelin-dependent cell attachment. Published by Elsevier Ireland Ltd.

引用

页码：263 / 274

页数：12

共 42 条

[11]

Eagle, 1997, Oncologist, V2, P324

[12] Precursor lesions of ovarian epithelial malignancy [J].

Feeley, KM ;

Wells, M .

HISTOPATHOLOGY, 2001, 38 (02) :87-95

[13] Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library [J].

Feldhaus, MJ ;

Siegel, RW ;

Opresko, LK ;

Coleman, JR ;

Feldhaus, JMW ;

Yeung, YA ;

Cochran, JR ;

Heinzelman, P ;

Colby, D ;

Swers, J ;

Graff, C ;

Wiley, HS ;

Wittrup, KD .

NATURE BIOTECHNOLOGY, 2003, 21 (02) :163-170

[14]

Fures R, 1999, COLLEGIUM ANTROPOL, V23, P189

[15] The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsies [J].

Galloway, ML ;

Murray, D ;

Moffat, DF .

HISTOPATHOLOGY, 2006, 48 (06) :767-769

[16] Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors [J].

Gubbels, Jennifer A. A. ;

Belisle, Jennifer ;

Onda, Masanori ;

Rancourt, Claudine ;

Migneault, Martine ;

Ho, Mitchell ;

Bera, Tapan K. ;

Connor, Joseph ;

Sathyanarayana, Bangalore K. ;

Lee, Byungkook ;

Pastan, Ira ;

Patankar, Manish S. .

MOLECULAR CANCER, 2006, 5 (1)

[17] Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer [J].

Hassan, R ;

Remaley, AT ;

Sampson, ML ;

Zhang, JL ;

Cox, DD ;

Pingpank, J ;

Alexander, R ;

Willingham, M ;

Pastan, I ;

Onda, M .

CLINICAL CANCER RESEARCH, 2006, 12 (02) :447-453

[18] Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis [J].

Hassan, R ;

Laszik, ZG ;

Lerner, M ;

Raffeld, M ;

Postier, R ;

Brackett, D .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2005, 124 (06) :838-845

[19] Mesothelin variant 1 is released from tumor cells as a diagnostic marker [J].

Hellstrom, Ingegerd ;

Raycraft, John ;

Kanan, Sandra ;

Sardesai, Niranjan Y. ;

Verch, Thorsten ;

Yang, Yi ;

Hellstrom, Karl Erik .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (05) :1014-1020

[20] Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients [J].

Ho, M ;

Hassan, R ;

Zhang, JL ;

Wang, QC ;

Onda, M ;

Bera, T ;

Pastan, I .

CLINICAL CANCER RESEARCH, 2005, 11 (10) :3814-3820

← 1 2 3 4 5 →